NEUP
Neuphoria Therapeutics Inc.
There isn't enough reported data to score NEUP yet.
NEUP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NEUP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NEUP PE Valuation
NEUP has no meaningful PE right now: it lost money over the past year.
NEUP Forward outlook
There aren't enough analyst estimates for NEUP to show an outlook.
NEUP Earnings Per Share
NEUP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $45.5K | -22% |
| Q3 2022 | $45.5K | -21% |
| Q2 2022 | $2M | +1720% |
| Q1 2022 | $2M | +1722% |
| Q4 2021 | $58K | -72% |
| Q3 2021 | $57.9K | -72% |
| Q2 2021 | $110.6K | -75% |
| Q1 2021 | $110.5K | -75% |
NEUP's revenue is shrinking: $15M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | 80% | N/A |
| Q4 2024 | -559% | N/A |
| Q4 2022 | -19265% | -8315 points |
| Q3 2022 | -3529% | +7420 points |
| Q2 2022 | -256% | +2831 points |
| Q1 2022 | -422% | +2665 points |
| Q4 2021 | -10950% | -9913 points |
| Q3 2021 | -10950% | -9913 points |
NEUP's operating margin was 80% last quarter, up 336 points from the same quarter a year ago.
NEUP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.3M | -129% |
| Q4 2025 | -$6.4M | -$3.1M |
| Q3 2025 | -$3.8M | +$638.4K |
| Q1 2025 | $11.5M | +$14.9M |
| Q4 2024 | -$3.4M | +$599.7K |
| Q3 2024 | -$4.4M | +$303.1K |
| Q1 2024 | -$3.5M | +$177.8K |
| Q4 2023 | -$4M | -$874.2K |
NEUP has burned cash in almost every quarter: −$12M over the past year, against $188,683 the year before.
NEUP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -19% | -1M shares |
| 1 year | +156% | +2.7M shares |
NEUP has 4M diluted shares, up 156% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $554,738 |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
NEUP Net Leverage
NEUP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NEUP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 2.8 | Oversold |
NEUP's weekly RSI is 30 (neutral) and its Stochastic is 3 (oversold).
NEUP PE vs Healthcare Sector
NEUP has no meaningful PE right now: it lost money over the past year.
NEUP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.20 | 19% below |
| 20 week MA | $3.50 | 26% below |
| 50 week MA | $4.07 | 37% below |
| 100 week MA | $5.48 | 53% below |
NEUP is in a downtrend: it's below all four of its weekly moving averages, and 53% below its 100-week average.
NEUP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $2.91 | $4.03 | +38% |
| 2025 | $4.03 | $3.72 | -7.7% |
| 2026 YTD | $3.72 | $2.58 | -31% |
NEUP has finished lower in one of the last two years. It's down 31% so far in 2026.